Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.64 |
| ▸ | CA2 | P00918 | 5/20 | 0.64 |
| ▸ | CA9 | Q16790 | 5/20 | 0.64 |
| ▸ | CA12 | O43570 | 4/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849447 | 0.84 | CA1 (0.68) | CA1CA2CA9CA12GLA | |
| SCHEMBL31018735 | 0.81 | CA1 (0.65) | CA1CA2CA9CA12GLA | |
| SCHEMBL1288179 | 0.81 | CA1 (0.55) | CA1CA2CA9CA12GLA | |
| SCHEMBL5145999 | 0.80 | CA1 (0.64) | CA1CA2CA9CA12GLA | |
| SCHEMBL5145990 | 0.80 | CA1 (0.64) | CA1CA2CA9CA12GLA | |
| SCHEMBL28927348 | 0.80 | LMNA (0.76) | CA1CA2CA9CA12GLA | |
| SCHEMBL25914166 | 0.79 | GLA (0.65) | CA1CA2CA9CA12GLA | |
| SCHEMBL29196466 | 0.79 | LMNA (0.74) | CA1CA2CA9CA12GLA | |
| SCHEMBL16151836 | 0.79 | GLA (0.78) | CA1CA2CA9CA12GLA | |
| SCHEMBL677158 | 0.79 | GLA (0.78) | CA1CA2CA9CA12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | CA1 1413/4885CA2 1485/4885CA9 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.